Fresh off Kite and BeiGene deals, Shore­line ups the ante with a hefty crossover. But the biotech in­sists it's in no rush

Though it may seem like Shore­line Bio­sciences is rapid­ly gain­ing mo­men­tum with a flur­ry of deals — and, now, a new fund­ing round — Klean­this Xan­thopou­los doesn’t feel he’s in a rush.

The biotech’s chief ex­ec­u­tive put the bow on a $140 mil­lion Se­ries B on Tues­day, as Shore­line con­tin­ues a streak of wheel­ing and deal­ing that’s seen it part­ner with Gilead’s Kite and BeiGene these last few months. And de­spite the new raise tech­ni­cal­ly be­ing a crossover round with Al­ly Bridge Group lead­ing the way, Xan­thopou­los is tak­ing his time in prep­ping a pub­lic of­fer­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER